Profile

Arthur W. Blackstock Jr, M.D.Wake Forest Baptist Health

Doctor Rating

4.8 out of 5

80 Ratings
11 Comments
 

Arthur W. Blackstock Jr, M.D.

Program Director,
Chair,
Professor,

Clinical Interests

Lung Cancer, Pancreatic Cancer

Contact Information

New Patient Appointments: 336-716-WAKE
Returning Patient Appointments: 336-713-3600
Department: 336-713-3600

Email: ablackst@wakehealth.edu

Insurance Accepted »

Media Medical Expert »

Education & Training

  • B.A., Wake Forest University, 1985
  • M.D., University of North Carolina-Chapel Hill, 1989
  • Internship, Pitt County Mem Hosp, 1990
  • Internship, Univ No Carolina Affil Hosps, 1994
  • Fellowship, North Carolina Baptist Hospita, 1994

Board Certifications

  • American Board of Radiology, Radiation Oncology

NPI Number

  • 1356323307
Arthur W. Blackstock Jr, M.D.

Doctor Rating

4.8 out of 5

80 Ratings
11 Comments
 

Arthur W. Blackstock Jr, M.D.

Program Director, Comprehensive Cancer Center
Chair, Radiation Oncology
Professor, Radiation Oncology
Cancer Biology

Contact Information

Academic: 336-713-3600 | Department: 336-713-3600

Email: ablackst@wakehealth.edu

Media Medical Expert »

Recent Publications

Image guided radiation therapy may result in improved local control in locally advanced lung cancer patients. Kilburn JM, Soike MH, Lucas JT, Ayala-Peacock D, Blackstock W, Isom S, Kearns WT, Hinson WH, Miller AA, Petty WJ, Munley MT, Urbanic JJ.. Pract Radiat Oncol. 2016;6(3):e73-e80.

Is a clinical target volume (CTV) necessary in the treatment of lung cancer in the modern era combining 4-D imaging and image-guided radiotherapy (IGRT)?. Kilburn JM, Lucas JT, Soike MH, Ayala-Peacock DN, Blackstock AW, Hinson WH, Munley MT, Petty WJ, Urbanic JJ.. Cureus. 2016;8(1):e466.

A cortical thickness and radiation dose mapping approach identifies early thinning of ribs after stereotactic body radiation therapy. Okoukoni C, Lynch SK, McTyre ER, Randolph DM, Weaver AA, Blackstock AW, Lally BE, Munley MT, Willey JS.. Radiother Oncol. 2016;119(3):449-453.

Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. De Ruysscher D, Lueza B, Le Pechoux C, Johnson DH, O'Brien M, Murray N, Spiro S, Wang X, Takada M, Lebeau B, Blackstock W, Skarlos D, Baas P, Choy H, Price A, Seymour L, Arriagada R, Pignon JP.. Ann Oncol. 2016;():.

The multidisciplinary approach to the treatment of rectal cancer: 2015 update. Onyeuku NE, Ayala-Peacock DN, Russo SM, Blackstock AW.. Expert Rev Gastroenterol Hepatol. 2015;9(4):507-517.

ACR Appropriateness Criteria resectable stomach cancer. Daroui P, Jabbour SK, Herman JM, Abdel-Wahab M, Azad N, Blackstock AW, Das P, Goodman KA, Hong TS, Jones WE III, Kaur H, Konski AA, Koong AC, Kumar R, Pawlik TM, Small W Jr, Thomas CR Jr, Suh WW.. Oncology (Williston Park). 2015;29(8):595-603.

Phase IB/II study of neoadjuvant chemoradiotherapy with CRLX101 and capecitabine for locally advanced rectal cancer [abstract]. Wang A, Sanoff HK, McRee AJ, O'Neil BH, Calvo BF, Hennessy MG, Murphy C, Tynan TM, Blackstock AW, Garmey EG, Tepper JE.. J Clin Oncol. 2015;33(15 Suppl):TPS3629.

ACR Appropriateness Criteria local excision in early stage rectal cancer. Russo S, Blackstock AW, Herman JM, Abdel-Wahab M, Azad N, Das P, Goodman KA, Hong TS, Jabbour SK, Jones WE III, Konski AA, Koong AC, Kumar R, Rodriguez-Bigas M, Small W Jr, Thomas CR Jr, Suh WW.. Am J Clin Oncol. 2015;38(5):520-525.

Thoracic SBRT induces early deterioration of cortical bone in ribs [abstract]. Okoukoni C, Lynch S, Weaver A, Blackstock AW, Lally BE, Munley MT, Willey J.. Int J Radiat Oncol Biol Phys. 2015;93(3 Suppl):S83.

Acute cortical bone thinning in the femoral head after pelvic radiation therapy [abstract]. Randolph DM II, Okoukoni C, Isom S, Munley MT, Lally BE, Blackstock AW, Willey J.. Int J Radiat Oncol Biol Phys. 2015;93(3 Suppl):E491-E492.

ACR appropriateness criteria-anal cancer. Hong TS, Petz JL, Herman JM, Abdel-Wahab M, Azad N, Blackstock AW, Das P, Goodman KA, Jabbour SK, Jones WE III, Konski AA, Koong AC, Rodriguez-Bigas M, Small W Jr, Thomas CR Jr, Zook J, Suh WW.. Gastrointest Cancer Res. 2014;7(1):4-14.

Management of mediastinal relapse after treatment with stereotactic body radiotherapy or accelerated hypofractionated radiotherapy for stage I/II non-small-cell lung cancer. Kilburn JM, Lester SC, Lucas JT Jr, Soike MH, Blackstock AW, Kearns WT, Hinson WH, Miller AA, Petty WJ, Munley MT, Urbanic JJ.. J Thorac Oncol. 2014;9(4):572-576.

Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatment. Kilburn JM, Kuremsky JG, Blackstock AW, Munley MT, Kearns WT, Hinson WH, Lovato JF, Miller AA, Petty WJ, Urbanic JJ.. Radiother Oncol. 2014;110(3):505-510.

Comparison of accelerated hypofractionation and stereotactic body radiotherapy for Stage 1 and node negative Stage 2 non-small cell lung cancer (NSCLC). Lucas JT Jr, Kuremsky JG, Soike M, Hinson WW, Kearns WT, Hampton CJ, Blackstock AW, Urbanic J.. Lung Cancer. 2014;85(1):59-65.

Which lung tumors shrink during fractionated radiation and how does this influence outcome?: Appropriately selecting tumor and treatment characteristics for adaptive radiation therapy protocols [abstract]. Kilburn JM, Lucas JT, Soike MH, Ayala-Peacock D, Kuremsy JG, Blackstock A, Hinson WH, Miller AA, Petty WJ, Munley MT, Urbanic JJ.. Int J Radiat Oncol Biol Phys. 2014;90(Suppl 1):S641-S642.

An evaluation of toxicity using accumulated total dose based on EQD2 for thoracic reirradiation incorporating at least 1 course of SBRT [abstract]. Lester SC, Kilburn JM, Lucas JT, Soike MH, Blackstock AW, Hinson WH, Miller AA, Petty WJ, Munley MT, Urbanic JJ.. Int J Radiat Oncol Biol Phys. 2014;90(Suppl 1):S640-S641.

ACR appropriateness criteria rectal cancer: metastatic disease at presentation. Goodman KA, Milgrom SA, Herman JM, Abdel-Wahab M, Azad N, Blackstock AW, Das P, Hong TS, Jabbour SK, Jones WE III, Konski AA, Koong AC, Kumar R, Rodriguez-Bigas M, Small W Jr, Thomas CR Jr, Suh WW.. Oncology (Williston Park). 2014;28(10):.

The role of alveolar epithelium in radiation-induced lung injury. Almeida C, Nagarajan D, Tian J, Leal SW, Wheeler K, Munley M, Blackstock W, Zhao W.. PLoS One. 2013;8(1):e53628.

The impact of multimodality therapy of distal esophageal and gastroesophageal junction adenocarcinomas on treatment-related toxicity and complications. Monjazeb AM, Blackstock AW.. Semin Radiat Oncol. 2013;23(1):60-73.

A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma. Raftery L, Tepper JE, Goldberg RM, Blackstock AW, Aklilu M, Bernard SA, Ivanova A, Davies JM, O'Neil BH.. Am J Clin Oncol. 2013;36(3):250-253.

Stereotactic body radiation therapy (SBRT) and image guided accelerated hypofractionated radiation therapy (IGAHRT) for the treatment of oligometastatic cancers [abstract]. Ayala-Peacock DN, Blackstock AW, Kearns WT, Hinson WH, Munley MT, Miller AA, Petty WJ, Urbanic JJ.. Int J Radiat Oncol Biol Phys. 2013;87(2 Suppl):S567-S568.

Is a clinical target volume (CTV) necessary in treatment of thoracic malignancies treated in the modern era combining 4-D imaging and image guided radiation therapy (IGRT)? [abstract]. Kilburn JM, Lucas JT, Soike MH, Ayala-Peacock D, Blackstock AW, Kearns WT, Hinson WH, Miller AA, Petty WJ, Urbanic JJ.. Int J Radiat Oncol Biol Phys. 2013;87(2 Suppl):S549.

Multiple courses of thoracic radiation therapy (XRT) using stereotactic body radiation therapy (SBRT) as the first or second course of treatment for tumors outside the original high-dose region [abstract]. Kilburn JM, Lester SC, Lucas JT, Blackstock AW, Kearns WT, Hinson WH, Munley MT, Miller AA, Petty WJ, Urbanic JJ.. Int J Radiat Oncol Biol Phys. 2013;87(2 Suppl):S36.

Salvage radiation for mediastinal relapse after treatment with accelerated hypofractionated radiation therapy (AHRT) or stereotactic body radiation therapy (SBRT) for stage I/II NSCLC [abstract]. Lester SC, Kilburn JM, Lucas JT, Munley MT, Blackstock AW, Kearns WT, Hinson WH, Miller AA, Petty WJ, Urbanic JJ.. Int J Radiat Oncol Biol Phys. 2013;87(2 Suppl):S543-S544.

The 'watch-and-wait' approach for rectal cancer: are outcomes improved with more limited T stage and routine use of MRI for staging? [comment]. Russo S, Blackstock AW Jr.. Oncology (Williston Park). 2013;27(10):976-977.

Image guided radiation therapy results in mproved local control in lung cancer patients treated with fractionated radiation therapy for stage IIB-IIIB disease [abstract]. Soike M, Kilburn JM, Lucas JT, Ayala-Peacock D, Blackstock AW, Kearns WT, Hinson WH, Miller AT [sic] [Miller AA], Petty WJ, Urbanic JJ.. Int J Radiat Oncol Biol Phys. 2013;87(2 Suppl):S547-S548.

A pilot 11C-choline PET/CT imaging study investigating the ability to detect occult metastatic osseous disease in newly diagnosed high-risk prostate adenocarcinoma. Ayala-Peacock DN, Onyeuku N, Thomas AJ, Garg P, Blackstock AW.. Pract Radiat Oncol. 2013;3(2 Suppl 1):S27.

A pilot 11C-choline PET-CT imaging study in patients with locally advanced esophageal cancer. Ayala-Peacock DN, Thomas AJ, Smith H, Garg P, Blackstock AW.. Pract Radiat Oncol. 2013;3(2 Suppl 1):S23.

Smoking cessation counseling beliefs and behaviors of outpatient oncology providers. Weaver KE, Danhauer SC, Tooze JA, Blackstock AW, Spangler J, Thomas L, Sutfin EL.. Oncologist. 2012;17(3):455-462.

The role of chemoradiation for patients with resectable or potentially resectable pancreatic cancer. Kimple RJ, Russo S, Monjazeb A, Blackstock AW.. Expert Rev Anticancer Ther. 2012;12(4):469-480.

ACR Appropriateness Criteria: resectable rectal cancer. Jones WE III, Thomas CR Jr, Herman JM, Abdel-Wahab M, Azad N, Blackstock W, Das P, Goodman KA, Hong TS, Jabbour SK, Konski AA, Koong AC, Rodriguez-Bigas M, Small W Jr, Zook J, Suh WW.. Radiat Oncol. 2012;7():161.

Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial. Socinski MA, Stinchcombe TE, Moore DT, Gettinger SN, Decker RH, Petty WJ, Blackstock AW, Schwartz G, Lankford S, Khandani A, Morris DE.. J Clin Oncol. 2012;30(32):3953-3959.

Impact of marital status and race on survival for patients with colon cancer: an analysis of data from the Surveillance, Epidemiology, and End-Results (SEER) Program [abstract]. Blackstock A, Lally B, Isom S, Paskett E.. Int J Radiat Oncol Biol Phys. 2012;84(3 Suppl):S539.

Thoracic reirradiation in patients with stereotactic body radiation therapy (SBRT) as first or second course of treatment [abstract]. Kilburn JM, Kuremsky JG, Blackstock AW, Kearns WT, Hampton CJ, Hinson WH, Miller AA, Petty WJ, Urbanic JJ.. Int J Radiat Oncol Biol Phys. 2012;84(3 Suppl):S604.

Hypofractionated radiation therapy for stage I and II non-small cell lung cancer [abstract]. Kuremsky JG, Petty WJ, Miller A, Hinson WH, Hampton CJ, Blackstock AW, Urbanic JJ.. Int J Radiat Oncol Biol Phys. 2012;84(3 Suppl):S153-S154.

Long-term follow-up and patterns of failure for patients with medically inoperable stage I non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT) [abstract]. Urbanic JJ, Soike M, Hampton CJ, Lucas J, Hinson W, Kearns W, Blackstock AW.. Int J Radiat Oncol Biol Phys. 2012;84(3 Suppl):S609.

Thoracic re-irradiation in patients with stereotactic body radiotherapy (SBRT) as first or second course of treatment [abstract]. Kilburn KM, Kuremsky JG, Blackstock AW, Kearns WT, Hampton CJ, Hinson WH, Miller AA, Petty WJ, Urbanic JJ.. J Thorac Oncol. 2012;7(9 Suppl 4):S253-S254.

Hypofractionated radiotherapy for stage I and II non-small cell lung cancer [abstract]. Kuremsky JG, Petty WJ, Miller A, HInson WH, Hampton CJ, Blackstock AW, Urbanic JJ.. J Thorac Oncol. 2012;7(9 Suppl 4):S230.

Comparison of accelerated hypofractionation and stereotactic body radiotherapy for stage 1 & 2 non-small cell lung cancer (NSCLC) [abstract]. Lucas JT, Kuremsky JG, Soike M, Hinson W, Kearns WT, Hampton CJ, Blackstock AW, Urbanic JJ.. J Thorac Oncol. 2012;7(9 Suppl 4):S228.

Long-term follow-up and patterns of failure for patients with medically inoperable Stage I non-small cell lung cancer (NSCLC) treated with stereotactic body radiotherapy (SBRT) [abstract]. Urbanic JJ, Soike M, Hampton CJ, Lucas J, Hinson W, Kearns W, Blackstock AW.. J Thorac Oncol. 2012;7(9 suppl 4):S288.

Was F-18 fluorodeoxyglucose positron emission tomography complete response after chemoradiotherapy defined as standardized uptake value(max-1 hour) less than or equal to 3 complete? [reply to letter]. Monjazeb AM, Blackstock AW.. J Clin Oncol. 2011;29(9):E249-E250.

Phase I/II trial of bevacizumab (B) and erlotinib (E) with induction (IND) and concurrent (CON) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic conformal radiotherapy (TCRT) in stage III non-small cell lung cancer (NSCLC) [abstract]. Stinchcombe T, Socinski MA, Moore DT, Gettinger SN, Decker RH, Petty WJ, Blackstock AW, Schwartz G, Lankford S, Morris DE.. J Clin Oncol. 2011;29(Suppl):abstr 7016.

A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : Cancer and Leukemia Group B (CALGB) 80003. Mamon HJ, Niedzwiecki D, Hollis D, Tan BR, Mayer RJ, Tepper JE, Goldberg RM, Blackstock AW, Fuchs CS.. Cancer. 2011;117(12):2620-2628.

The chemokine, CCL3, and its receptor, CCR1, mediate thoracic radiation-induced pulmonary fibrosis. Yang X, Walton W, Cook DN, Hua X, Tilley S, Haskell CA, Horuk R, Blackstock AW, Kirby SL.. Am J Respir Cell Mol Biol. 2011;45(1):127-135.

Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. Yothers G, Sargent DJ, Wolmark N, Goldberg RM, O'Connell MJ, Benedetti JK, Saltz LB, Dignam JJ, Blackstock AW.. J Natl Cancer Inst. 2011;103(20):1498-1506.

The utility of 11C-choline positron emission tomography computerized tomography (PET-CT) for staging locally advanced esophageal cancer [abstract]. Attia A, Vern-Gross T, Garg PK, Garg S, Thomas A, Smith H, Monjazeb A, Blackstock AW.. Int J Radiat Oncol Biol Phys. 2011;81(2 Suppl):S314.

Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 GY) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy:. Salama JK, Stinchcombe TE, Gu L, Wang X, Morano K, Bogart JA, Crawford JC, Socinski MA, Blackstock AW, Vokes EE.. Int J Radiat Oncol Biol Phys. 2011;81(4):e269-e274.

A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer. Center B, Petty WJ, Ayala D, Hinson WH, Lovato J, Capellari J [sic] [Cappellari J], Oaks T, Miller AA, Blackstock AW.. J Thorac Oncol. 2010;5(1):69-74.

Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904. Bogart JA, Hodgson L, Seagren SL, Blackstock AW, Wang X, Lenox R, Turrisi AT III, Reilly J, Gajra A, Vokes EE, et al.. J Clin Oncol. 2010;28(2):202-206.

Outcomes of patients with esophageal cancer staged with [18F] fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?. Monjazeb AM, Riedlinger G, Aklilu M, Geisinger KR, Mishra G, Isom S, Clark P, Levine EA, Blackstock AW.. J Clin Oncol. 2010;28(31):4714-4721.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Professor, Radiation Oncology

Clinical Interests

Lung Cancer, Pancreatic Cancer
Arthur W. Blackstock Jr, M.D.

Arthur W. Blackstock Jr, M.D.

Program Director, Comprehensive Cancer Center
Chair, Radiation Oncology
Professor, Radiation Oncology
Cancer Biology

Doctor Rating

4.8 out of 5

Arthur W. Blackstock Jr, M.D.80 Ratings
11 Comments


 

Doctor Ratings

The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Press Ganey Patient Satisfaction Survey

CP concern for questions/worries
4.9
CP efforts to include in decisions
4.8
CP explanations of prob/condition
4.9
CP spoke using clear language
4.8
Friendliness/courtesy of CP
4.9
Likelihood of recommending CP
4.9
Patients' confidence in CP
4.9
Time CP spent with patient
4.8
Wait time at clinic
4.6



Patient Comments

Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.

4/29/2016

Dr. Blackstock was good about talking about my radiation treatment and even sharing what I could expect when I went to hematology/oncology. However, the information there was different than what I expected. It felt like I was getting a new, and much worse, diagnosis and was taking my hope away. A more positive incidence was when I was struggling with not being able to sleep, Dr.Blackstock ordered medication and just getting rest made it possible for me to feel more "normal" and ready to face the diagnosis.

3/2/2016

*Dr. Blackstock & *Dr. Farris were outstanding in gathering information and then presenting their recommendations on my condition - they are very knowledgeable and professional.

1/25/2016

I had a good experience

1/6/2016

Excellent care!!!

1/6/2016

Dr. was WONDERFUL....very personable and made us feel at ease!

11/10/2015

The best.

10/29/2015

The doctor allowed most communication to be provided, by his resident. His resident informed me that a medication would be prescribed but the doctor didn't explain it's purpose or discuss it with me.

10/15/2015

All good.

10/6/2015

*Dr. Blackstock is a very good doctor. He cares about his patients.

9/27/2015

he is very compassionate and mindful of not keeping patients waiting

9/21/2015

*Dr. Blackstone is a physician who cares and provides top quality care.

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
Magnet Hospital RecognitionConsumer Choice2015 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.